Neos Therapeutics

$1.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-2.09%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell NEOS and other stocks, options, ETFs, and crypto commission-free!

About NEOS

Neos Therapeutics, Inc. Common Stock, also called Neos Therapeutics, is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Read More Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.

Employees
215
Headquarters
Grand Prairie, Texas
Founded
1994
Market Cap
93.00M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
238.33K
High Today
$1.99
Low Today
$1.86
Open Price
$1.91
Volume
123.71K
52 Week High
$6.00
52 Week Low
$1.13

Collections

NEOS News

ReutersAug 16

Edited Transcript of NEOS earnings conference call or presentation 8-Aug-19 12:30pm GMT

12

NEOS Earnings

-$0.60
-$0.43
-$0.25
-$0.08
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, Pre-Market

More NEOS News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.